SG Americas Securities LLC Increases Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

SG Americas Securities LLC increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 80.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 135,824 shares of the medical equipment provider’s stock after buying an additional 60,712 shares during the quarter. SG Americas Securities LLC owned about 0.07% of Zimmer Biomet worth $15,373,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ZBH. Roman Butler Fullerton & Co. acquired a new stake in Zimmer Biomet during the fourth quarter worth $473,000. KLCM Advisors Inc. acquired a new stake in Zimmer Biomet during the fourth quarter worth $7,825,000. Van ECK Associates Corp increased its stake in Zimmer Biomet by 5.9% during the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after acquiring an additional 218,688 shares during the last quarter. MFG Wealth Management Inc. acquired a new stake in Zimmer Biomet during the fourth quarter worth $1,506,000. Finally, Asset Management One Co. Ltd. increased its stake in Zimmer Biomet by 0.7% during the fourth quarter. Asset Management One Co. Ltd. now owns 81,913 shares of the medical equipment provider’s stock worth $8,754,000 after acquiring an additional 602 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 2.2%

Shares of NYSE ZBH opened at $94.85 on Wednesday. The company has a market capitalization of $18.77 billion, a price-to-earnings ratio of 21.32, a price-to-earnings-growth ratio of 1.95 and a beta of 0.72. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The business has a 50-day moving average of $97.20 and a two-hundred day moving average of $103.88. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.94 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet’s payout ratio is currently 21.24%.

Analyst Ratings Changes

ZBH has been the subject of several recent analyst reports. Wells Fargo & Company cut their target price on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Royal Bank of Canada dropped their price objective on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Canaccord Genuity Group dropped their price objective on Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating for the company in a research note on Monday, May 12th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research note on Tuesday, May 6th. Finally, JMP Securities dropped their price objective on Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $111.53.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.